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Abstract
Eradication of HIV infection will require the identification of all cellular reservoirs that harbor
latent infection. Despite low or lack of CD4 receptor expression on Vδ2 T cells, infection of
these cells has previously been reported. We found that upregulation of the CD4 receptor
may render primary Vδ2 cells target for HIV infection in vitro and we propose that HIV-
induced immune activation may allow infection of γδ T cells in vivo. We assessed the pres-
ence of latent HIV infection by measurements of DNA and outgrowth assays within Vδ2
cells in 18 aviremic patients on long-standing antiretroviral therapy. In 14 patients we recov-
ered latent but replication-competent HIV from highly purified Vδ2 cells demonstrating that
peripheral Vδ2 T cells are a previously unrecognized reservoir in which latent HIV infection
is unexpectedly frequent.
Author Summary
Antiretroviral therapy (ART) has led to a decreased HIV-related morbidity and mortality
across the world. While successful ART restores health, it does not cure infection as latent
HIV-1 remains integrated within different cell populations, unaffected by ART. To date
resting memory CD4+ T cells are the best-characterized cellular reservoir. However, eradi-
cation of HIV-1 infection requires the description of all latent cellular reservoirs harboring
replication-competent HIV-1. We describe the discovery of an unexpected cellular reser-
voir within γδ T lymphocytes. This novel reservoir must be considered as strategies to
clear latent HIV are developed and tested.
Introduction
The infecting HIV genome integrates into host chromatin where, transcriptionally silent and
unaffected by antiretroviral therapy (ART), it represents a major challenge towards efforts to
eradicate infection [1]. Virologic latency is defined as durable, quiescent infection from which
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replication-competent HIV can emerge after cell activation. To date, resting memory CD4+ T
lymphocytes are the major cell type in which latency has been documented in vivo [2–5]. How-
ever, efforts to eradicate HIV infection require the identification of all potential cellular reser-
voirs and therefore, while conventional αβ T cells, which include resting memory CD4+ T cells,
constitute the major subpopulation of T lymphocytes, the γδ T cell population merits study as
a potentially important site of latent infection.
In the absence of pathological conditions such as infection, γδ T cells represent between 2
and 10% of total circulating CD3+ T lymphocytes [6]. Among peripheral CD3+ γδ T cells,
those expressing a TCR formed by the Vγ9 and Vδ2 variable regions (hereafter referred to as
Vδ2 cells) constitute up to 90% of γδ T cells [7]. These Vδ2 cells specifically recognize non-pep-
tidic phosphorylated metabolites of isoprenoid biosynthesis, such as the potent activator (E)-
4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), present in most pathogenic bacteria
[8,9], or isopentenyl pyrophosphate (IPP), produced also by the human mevalonate biosynthe-
sis pathway [10], but are not recognized by conventional αβ T cells. In vitro, both compounds
have the same effect on γδ T cells, activating them. In adults, most Vδ2 cells are memory cells
that can be further classified according to expression of CD45RO and CD27 surface markers
[11–13].
During HIV-1 infection, the peripheral blood Vδ2 cell subset is depleted while Vδ1 cells are
expanded, leading to an inversion of the Vδ2/Vδ1 ratio [14,15]. An indirect mechanism involv-
ing CCR5/α4β7 signalling was hypothesized to explain the specific depletion of Vδ2 cells [16].
However, an additional mechanism may be the direct infection of these cells as productive
HIV infection of γδ T cells within peripheral blood mononuclear cells (PBMC) [17] as well as
infection of γδ T cell clones by the CXCR4-tropic laboratory clone HIVLAI [18] has been
reported. Similarly, SIV can infect both Vδ1 and Vδ2 cells, albeit infrequently [19]. Despite the
documented capacity of HIV to infect γδ T cells, the potential of γδ T cells to serve as a persis-
tent reservoir of infection has not been studied. Moreover, the memory phenotype of Vδ2 cells
suggests that these cells could play a role as durable in vivo reservoirs of HIV infection. Using a
viral outgrowth assay to detect latent but replication-competent HIV [20,21], complemented
by measures of HIV DNA, we demonstrate for the first time that peripheral Vδ2 cells in ART-
treated patients with complete suppression of HIV plasma viremia harbour latent HIV that can
replicate following ex vivo induction. We report the discovery of a new reservoir of HIV within
peripheral Vδ2 cells, and suggest that infection in this population may be founded by immune
activation that transiently upregulates the CD4 receptor on Vδ2 cells.
Results
Patients’ characteristics
To study the role of Vδ2 cells as reservoirs of persistent, latent HIV infection, 18 HIV-infected
male volunteers, who initiated ART in acute HIV infection (AHI; n = 9) or in chronic HIV
infection (CHI; n = 9) and received stable ART for a median of 3.4 years [range 1.9–9.5] were
studied. A comparison between AHI and CHI-treated patients’ characteristics at the time of
study showed that CHI patients had, as expected, a statistically significant lower nadir CD4
count (p = 0.017) and a significantly longer time on ART (p = 0.004). Median CD8+ T cell
count was lower and pre-therapy plasma HIV RNA was higher in the AHI patients although
these differences did not achieve statistical significance (Table 1).
Purity of Vδ2 cells
To ensure that other contaminating cells did not contribute to the recovery of HIV from iso-
lated Vδ2 cells, we incubated freshly isolated patients’ PBMC with raltegravir and abacavir for
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24 hours to avoid the possibility that de novo integration events could occur ex vivo after cell
donation. γδ T cells were then enriched from PBMC using magnetic immunoaffinity beads,
and non-activated (HLA-DR-) Vδ2 cells were further purified by FACS-sorting (Fig 1A and
1B). This process excluded αβTCR+ cells (classical CD4+ T cells) from pre-sort samples (Fig
1C), as detailed in Materials and Methods. To further confirm that Vδ2 cells were not already
activated, aliquots of isolated Vδ2 cells were cultured in 5U/mL IL-2 prior to the addition of
target cells in the viral outgrowth assay. HIV p24 measurements from these cultures were uni-
formly negative.
Vδ2 cells contain proviral HIV DNA
Total HIV DNA levels were then quantified in isolated Vδ2 cells, unfractionated PBMC and
total resting CD4+ T (r-CD4) cells, when available (Fig 2A) in patients treated in AHI and
CHI. As previously published in studies of other cell populations [22], DNA levels varied
widely but interestingly, Vδ2 cells showed the highest level of polHIV DNA copies per 106 Vδ2
cells (mean of 873.6 HIV copies/106 cells). Due to the low number of Vδ2 cells available for
analysis the limit of quantitation of Vδ2 cells was 50.6 copies/106 cells, and 5.1 copies/106 cells
for the other cell populations, where more cells could be analyzed. HIV DNA levels within Vδ2
cells were not statistically different between AHI and CHI-treated patients (p = 0.37). Within
PBMC and r-CD4 cells HIV DNA levels were higher in CHI patients than in AHI patients,














AHI A.1 840 6.86 870 552 2.44 2.22
A.2 600 5.27 599 684 2.15 1.55
A.3 371 5.19 629 398 3.38 3.22
A.4 137 6.24 776 592 4.04 3.12
A.5 277 7.93 615 464 6.46 3.99
A.6 520 4.36 698 470 0.98 0.77
A.7 606 6.06 864 940 1.38 1.36
A.8 474 7.00 967 684 0.94 0.5
A.9 409 4.40 931 1123 1.42 0.7
Median 474 6.06 776 592 2.14 1.55
CHI C.1 n/a n/a 711 834 8.48 3.31
C.2 81 5.58 772 464 12.52 2.76
C.3 195 4.86 1027 652 26.93 4.29
C.4 322 5.57 830 1014 3.01 2.72
C.5 602 5.88 1120 1013 5.31 4.98
C.6 180 5.24 727 1036 20.12 11.83
C.7 232 4.80 495 775 3.41 2.87
C.8 243 5.39 608 925 19.99 3.97
C.9 338 5.27 1145 1117 3.14 0.07
Median 238 5.32 772 925 8.48 3.31
p* 0.043 0.38 0.69 0.09 0.004 0.058
† VL = Viral Load before suppression
*Mann-Whitney U-test
n/a = not available.
doi:10.1371/journal.ppat.1005201.t001
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although this difference did not achieve statistical significance (p = 0.06 for PBMC and
p = 0.65 for resting CD4+ T cells). We recovered an average of 638.6 HIV DNA copies/million
γδ T cells from CHI patients, and an average of 1108.7 copies/ million from AHI patient. Con-
versely, we recovered an average of 30.3 HIV DNA copies/ million rCD4 cells from CHI
patients and an average of 21.4 copies/ 106 rCD4 cells from AHI patients. We calculated the
contribution of HIV DNA in Vδ2 cells and r-CD4 cells to the total HIV-DNA+ PBMC (Fig 2B)
as follows: First, we calculated the total HIV DNA copies in each cell population by multiplying
the average HIV copy number per million cells to the percentage of Vδ2 or r-CD4 cells present
in total PBMC. Then, this total HIV copy number was divided by the total HIV copy number
in PBMC to obtain the proportion of HIV corresponding to Vδ2or r-CD4 populations. Vδ2
cells contributed 1.6% and 8.1% to the total HIV DNA copy numbers in PBMC of CHI and
AHI patients, respectively. Resting CD4 T cells contributed 4.9% to the total HIV DNA copy
number in PBMC of CHI patients and 1.9% in AHI patients. None of the comparisons between
cell types or type of patients were statistically different.
Fig 1. Vδ2 T cell sorting strategy and purity. A) An example of the gating strategy to sort pre-enriched Vδ2 cells (panel 1) using a 2-step doublet
discrimination (panels 2 and 3), showing that CD3+ Vδ2 cells (panel 4) lack expression of HLA-DR (panel 5). B) Dot plot examples showing lack of αβ-TCR
(panel 6) and CD4 (panel 7) expression in the presort sample.C) Purity of the sorted cell population. After the sort an aliquot of sorted cells was acquired and
analyzed. Plots show high purity of CD3+ Vδ2 cells (panel 8) and lack of HLA-DR expression (panel 9). Post-sort analysis shows lack of αβ-TCR and CD4
(panels 10 and 11).
doi:10.1371/journal.ppat.1005201.g001
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Vδ2 cells are a novel reservoir for replication-competent HIV
We performed viral outgrowth assays using highly purified Vδ2 cells to demonstrate the recov-
ery of replication-competent HIV after, but not prior to, activation of Vδ2 cells from HIV-1
infected patients on fully suppressive ART. As expected, percentages of CD3+Vδ2 cells were
lower in patients treated in CHI compared to patients treated in AHI (mean 0.25% vs. 0.77%;
Table 2). Replication-competent HIV was detected in at least one culture replicate in 14 out of
18 patients (78%), with no virus recovered in two AHI and two CHI patients. Overall, for AHI
patients we assayed 94 cultures of which 21 were positive for HIV p24, compared to 53 total
cultures for CHI patients with virus recovered in 20 (22.3% vs. 37.7%; Table 2). Therefore, rep-
lication-competent virus was more frequently recovered from patients treated in CHI than
from AHI-treated patients. In parallel to these assays and as part of other projects in the lab,
viral outgrowth assays with isolated r-CD4 cells were performed as previously described
Fig 2. Quantification of total HIV DNA levels. A) Total polHIV copies were quantified by ddPCR within Vδ2
cells (n = 12), total resting CD4+ T cells (r-CD4) (n = 8) and unfractionated PBMC (n = 12) from HIV-1
suppressed patients treated in the acute HIV infection (AHI) or in the chronic HIV infection (CHI). Limit of
quantitation (LOQ) was 50.6 copies/ 106 Vδ2 cells and 5.1 copies/ 106 r-CD4 cells and PBMC, and is
depicted with a dotted line. Each color represents one patient.B) Pie charts reflecting the contribution of Vδ2
cells (purple) and r-CD4 cells (red) to the total HIV DNA+ PBMC in CHI patients (left pie) and AHI patients
(right pie).
doi:10.1371/journal.ppat.1005201.g002
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[21,23,24]. A summary of the outgrowth assays for r-CD4 cells is included in Table 2. Our
results show that Vδ2 cells constitute a novel reservoir for HIV infection that may persist for
years as latent Vδ2 cell infection was detected in CHI patients despite long-term suppressive
ART and the lack of intermittent low-level viremia (“blips”) during the prior two years of clini-
cal follow-up (Table 1). In addition, we analyzed two patients (C.2 and C.3) one year after
their first evaluation, and replication-competent HIV was again recovered from their Vδ2 cells
(S1 Fig). An expanded longitudinal analysis is underway to assess the stability of this reservoir.
In ten of the 14 patients in whom virus was recovered (A.2, A.3, A.5, A.6, A.7, C.2, C.3, C.6,
C.7 and C.9) HIV was detected in cultures of only 5000 cells, suggesting a high frequency of
infection within Vδ2 cells (Fig 3).
Next, we calculated the frequency of infection expressed as infectious units per million
(IUPM) isolated Vδ2 cells in 14 patients with available cell dilutions (seven AHI and seven
CHI) (Fig 4A). In addition, IUPM r-CD4 cells from the same patients were calculated to com-
pare both cell populations. Percentages of r-CD4 cells, number of cells cultured and total num-
ber of positive and total cells assayed are shown in Table 2. As expected, the confidence
interval for Vδ2 cells was much greater than for r-CD4 cells due to the lower number of Vδ2
Table 2. Detection of replication-competent HIV and HIV DNA from isolated Vδ2 cells and resting CD4+ T cells (r-CD4).















A.1 1.2 1/15 6.50 2500 12.9 1/24 33.6 n/a
A.2 0.9 5/11 3.50 113.2 12.6 5/32 38.8 38.7
A.3 0.8 3/11 4.30 n/a n/a 0/25 8.5 n/a
A.4 0.1 0/2 1.60 n/a n/a 9/19 3.3 n/a
A.5 0.1 1/3 0.15 n/a 10.5 12/30 48.6 n/a
A.6 n/a 3/14 1.90 n/a 22.8 12/34 30 n/a
A.7 0.7 7/22 6.10 1719.5 22.3 10/28 28.8 n/a
A.8 1.8 1/10 3.20 1652.1 13.3 18/30 33.8 n/a
A.9 0.6 0/6 3.00 <LOQ 12.3 25/36 48.8 25.4
A.10 0.5 n/a n/a 667.25 10.3 n/a n/a <LOQ
Mean 0.77 21/94 3.00 1108.6 15.3 92/258 30.5 21.3
C.1 0.2 1/1 0.80 85.7 18.1 1/36 48.8 4.77
C.2 0.4 3/4 0.95 1569.6 13.4 24/30 48.6 n/a
C.3 n/a 2/4 0.95 n/a 16.8 4/27 41.1 n/a
C.4 n/a 0/1 0.80 n/a n/a 16/36 12.4 n/a
C.5 0.3 0/4 0.95 <LOQ 10.3 9/34 7.3 89.9
C.6 0.3 5/6 0.75 81.0 15.6 1/30 19.1 21.1
C.7 n/a 6/12 2.35 n/a 14.4 22/30 48.6 n/a
C.8 0.1 1/12 1.6 144.2 15.7 18/30 33.8 5.2
C.9 0.2 2/9 1.50 n/a 17.5 11/30 33.8 n/a
C.10 0.9 n/a n/a 1951.1 n/a n/a n/a 94.5
Mean 0.25 20/53 1.18 638.6 15.2 106/283 32.6 35.9
*Percentage of peripheral CD3+ Vδ2 cells or **CD3+CD4+HLA-DR-CD69- cells within total PBMC. Antibody cocktail used to isolate r-CD4 cells did not
completely deplete γδ T cells.
n/a, not available.
LOQ, limit of quantitation.
doi:10.1371/journal.ppat.1005201.t002
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cells assayed and therefore the estimation of the frequency of infection is less accurate (Fig 4B).
However, we could not detect statistical differences when IUPM Vδ2 cells were compared to
IUPM r-CD4 cells, suggesting that despite the inaccuracy of the co-culture system, Vδ2 cells
may be frequently latently infected.
Interestingly, while quantifying the frequency of infection within Vδ2 cells by limiting dilu-
tion assay, in some patients we found an unusual pattern of recovery of HIV with more positive
wells at lower dilutions and no virus recovered when more cells were cultured (Fig 3). As γδ T
cells possess innate, nonspecific antiviral function [25,26], we hypothesized that an antiviral
activity of the uninfected γδ T cells might reduce the recovery of HIV in cultures with high cell
inputs, yielding the unusual pattern of viral outgrowth seen in some patients. To test this
hypothesis, we performed viral inhibition assays, co-culturing Vδ2 cells from a healthy, unin-
fected donor, with autologous CD4+ T cells that had been HIV-infected ex vivo at ratios of
1 CD4 cell and 0.1 or 0.01 γδ cells. Vδ2 T cells inhibited HIV production from infected CD4+ T
cells, with increased inhibition seen at higher cell inputs in the co-culture system (Fig 5). In
addition, in some wells we blocked the cytotoxic activity of γδ T cells by pre-incubating the iso-
lated Vδ2 cells with a cocktail of antibodies against CD8, NKG2D and CD16 (Fig 5). HIV p24
Fig 3. Recovery of replication-competent virus from isolated Vδ2 cells. Representation of the culture
conditions in isolated peripheral resting Vδ2 T cells in patients treated in acute HIV infection (AHI) and in
chronic HIV infection (CHI). Each square represents one culture replicate that is gray when replication-
competent HIV was recovered, and is open when culture replicates were negative. Vδ2 T cells were
recovered at a higher frequency in patients treated in AHI than in patients treated in CHI, allowing more
replicates for the outgrowth assays. However, HIV was more frequently recovered from CHI patients than
from AHI patients.
doi:10.1371/journal.ppat.1005201.g003
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production was 74.6% inhibited in the 1:0.1 ratio conditions and 41.8% in the 1:0.01 condi-
tions. When the cocktail of antibodies was used, these percentages decreased to 26.9% and
15.5% in the 1:0.1 and 1:0.01 ratios, respectively.
Fig 4. Frequency of replication-competent HIV expressed as infectious units per million (IUPM) cells. A) Comparison between the frequency of
infection within isolated Vδ2 cells between patients treated in the acute HIV infection (AHI) and patients treated in the chronic HIV infection (CHI). B) Point
estimate (95%CI) of the frequency of infection in isolated Vδ2 cells (circles) and resting CD4+ T (r-CD4) cells (triangles) in individual patients treated in AHI
(left panel) or treated in CHI (right panel). Open symbols means HIVp24 was below the limit of detection, that was <10.67 for Vδ2 cells in patient A6, <0.1 for
r-CD4 cells in patient A7, and <31.9 for Vδ2 cells in patient C3. C)Comparison of the point estimate of the frequency of infection between Vδ2 cells and r-
CD4 cells in patients treated in AHI (left panel) and patients treated in CHI (right panel). p> 0.05, Wilcoxon signed-ranked test.
doi:10.1371/journal.ppat.1005201.g004
Vδ2 Cells Harbor Replication-Competent HIV
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Mechanism of HIV infection
Isolated Vδ2 cells can be infected in vitro, [17,18] (S2 Fig) despite low or absent surface CD4
receptor expression prior to activation and HIV infection of these cells is inhibited by CD4
blockade [17], (S2 Fig). We further investigated the CD4-dependence of HIV infection in Vδ2
cells. Total PBMC from uninfected donors were activated with IL-2 alone or IPP and IL-2, and
surface marker expression was analyzed by flow cytometry (Fig 6A and S3 Fig). As expected,
CD4 receptor expression was detected on<0.3% of Vδ2 cells at day 0, but became detectable
on up to 25% of cells after six days of culture in the presence of IL-2 alone, or IPP and IL-2. All
increases were statistically significant (p<0.01; Fig 6A). Interestingly, treatment with exoge-
nous IL-2 alone induced CD4 expression to similar levels as did IPP and IL-2 (mean 15.3% and
15.9%, respectively). In contrast, none of these conditions significantly increased the surface
expression of CCR5 after six days in culture (Fig 6A). In addition, the activation status of Vδ2
cells was also assessed in the same cells by analyzing the expression of the MHC Class II
HLA-DR receptor, the IL2 receptor alpha chain CD25, and the activation marker CD38 (Fig
6B). After six days in culture with IL-2 alone or IPP and IL-2 the expression of these markers
was significantly increased (p<0.05 in all cases) although treatment with IL-2 alone induced
activation in no more than 20% of Vδ2 cells (Fig 6B).
Based on these results we hypothesized that immune activation, driven in this instance by
HIV infection, might upregulate CD4 expression on Vδ2 cells in vivo. To test this hypothesis
we measured surface expression of CD4 and CCR5 expression in Vδ2 cells donated by three
viremic patients diagnosed during the acute phase of HIV infection, prior to the initiation of
ART (Fig 7). Based on history and diagnostic testing, the estimated date of infection in these
patients was less than 23 days prior to sampling. Likely related to the pathological immune acti-
vation of acute HIV infection, 9.5%, 15.6% and 15.9% of Vδ2 cells expressed CD4 (Fig 7A), as
compared to<0.3% of Vδ2 cells in healthy donors. In addition, we also analyzed the percent-
age of Vδ2 cells that coexpressed CD4 and CCR5 (Fig 7B). This observation in these unique
patients supports our hypothesis that pathological immune activation in early HIV infection
Fig 5. Vδ2 cells exhibit potent anti-HIV activity in vitro. Isolated Vδ2 cells from healthy donors were co-
cultured with autologous in vitro infected HIV- CD4+ T cells at 1:0.1 or 1:0.01 ratios (CD4:Vδ2) for seven
days. HIV p24 production was inhibited in a cell-dose-dependent manner. When a cocktail of blocking
antibodies against CD8, CD16 and NKG2D were added, cytotoxic function of Vδ2 cells was partially
abrogated. Mean±SE of three different donors is represented.
doi:10.1371/journal.ppat.1005201.g005
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promotes the upregulation of CD4 expression in Vδ2 cells, making them targets for HIV infec-
tion in vivo.
Discussion
We have discovered that peripheral resting Vγ9Vδ2 cells can act as a cellular reservoir of per-
sistent, latent HIV infection. Using a gold-standard coculture assay that defines the presence of
latent infection, we find that the frequency of replication-competent virus in these cells is sub-
stantial, with virus recovered in as few as 5000 Vδ2 T cells that lack activation markers. This
unexpected finding is supported by the detection of HIV DNA within this cell population,
implying that at least a fraction of the HIV DNA detected within Vδ2 cells represents replica-
tion-competent virus.
Fig 6. Expression of CD4, CCR5 and activationmarkers on Vδ2 cells.PBMC fromHIV-uninfected donors
were cultured and treated with IL-2 alone or IPP and IL-2 for six days. The surface expression of CD4, CCR5,
and activation markers (HLA-DR, CD38 and CD25) on Vδ2 cells were analyzed by flow cytometry on days 0
and 6.A)Majority of peripheral Vδ2 cells do not express the CD4 receptor but CD4 is significantly upregulated
after six days in culture with IL-2 or with IPP and IL-2 (*p<0.01). However, CCR5 is expressed on the surface of
Vδ2 cells at baseline without a significant induction after treatments.B) Analysis of activation markers
(HLA-DR, CD25 and CD38) showed peak activation after six days of culture with IPP and IL-2 with moderate
activation by IL-2 alone (*p<0.05).
doi:10.1371/journal.ppat.1005201.g006
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We propose a mechanism to explain the infection of Vδ2 cells despite the absence of CD4
expression in their surface. As isolated Vδ2 cells can be infected in vitro we hypothesize that
the activated immune environment during untreated HIV infection induces transient CD4
upregulation, rendering Vδ2 cells permissive for HIV-1 infection, and founding a substantial
population of latently infected γδ cells. This hypothesis is supported in vivo by the detection of
expression of CD4 and CCR5 in Vδ2 cells in untreated patients in early acute HIV infection.
Latent infection of γδ cells could occur at other times as well, when cellular activation results in
upregulation of CD4 expression.
Recovery of purified Vδ2 cells was reduced in patients treated in CHI, compared to patients
treated in AHI, as there is a dramatic loss of Vδ2 cells early after infection with HIV [14,15,18].
Such depletion is only partially reversed by ART [27]. Remarkably, replication-competent HIV
was quantified in purified Vδ2 cells in 77% of patients who had been treated and suppressed
for a median of nearly four years. Although γδ T cells represent only a small fraction of the
Fig 7. Vδ2 cells from untreated recently HIV-infected patients express CD4 and CCR5. A)Dot plots from three recently infected patient (VP1, VP2 and
VP3) showing surface expression of CD4 and CCR5 on CD3+Vδ2+ cells, and on CD3+Vδ2- cells for comparison. B) Density plots showing the percentage of
Vδ2 cells coexpressing CD4 and CCR5 in the same three patients.
doi:10.1371/journal.ppat.1005201.g007
Vδ2 Cells Harbor Replication-Competent HIV
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total CD3+ T lymphocytes, frequency of infection within isolated Vδ2 cells was not statistically
different from that in r-CD4 cells. However, it is important to highlight that this estimation is
not as accurate as the estimation for r-CD4 cells, as reflected by the 95% confidence intervals,
because a significantly lower number of cells were assayed. It is also important to note that
maximum activation conditions were differently assayed for both cell populations. Our results
may overestimate the frequency of infection in γδ cells compared to r-CD4 cell calculations, as
viral outgrowth starts during the first 24 hours of incubation, when γδ cells can spread the
virus to the γδ-CD8-depleted-PBMC, required for Vδ2 cell activation. In addition, our data
suggest the possibility that the ratio of defective to replication-competent proviruses might be
lower in Vδ2 cells although future comprehensive sequence analysis will be required to fully
address this possibility. A relative deficiency of restriction factors such as APOBEC3G/3F
[28,29] in γδ T cells might explain these findings. In addition, a recent study has shown that
HIV DNAmight be present in cells other than conventional CD4+ T cells and myeloid cells
suggesting that HIV may persist in other cell types [30]. As γδ cells can be phenotypically clas-
sified using CD45RA and CD27 markers, it is possible that in some prior studies these cells
may have been included in the evaluation of HIV infection within the latently infected resting
memory cell population. Interestingly, our results and others [22] have shown that in some
patients, HIV DNA levels within r-CD4 cells are lower than in total PBMC, suggesting that in
those patients, other cell types might have a high contribution to total HIV DNA measure-
ments. In addition, activated T cells have also been reported to have a greater HIV DNA contri-
bution than r-CD4 cells [23,24]. Although we found higher levels of HIV DNA within isolated
γδ T cells, the rarity of these cells within PBMCmakes them to less frequent contributors to the
total reservoir than r-CD4 cells. Of note, the custom antibody cocktail used to isolate r-CD4
cells does not completely deplete the γδ T cells and therefore comparisons between r-CD4 cells
and γδ T cells are not totally accurate. We have begun studies to evaluate the exact contribution
of γδ T cells in assays using total r-CD4 cells.
Although we recovered HIV from low numbers of γδ T cells in 14 of 18 patients, in several
patients the recovery of replication-competent virus was less than expected in cultures with
higher Vδ2 cell input. In these cases, estimates of the frequency of infection cannot be made
with these data as such estimates depend on the assumption of a normal distribution of infec-
tion. We speculate that in these cultures, sufficient Vδ2 cells were present to exert potent antivi-
ral activity [25,26], leading to inhibition of spread of the virus during the outgrowth phase of
the assay. In support of this, we demonstrate a dose-dependent inhibition of the p24 produc-
tion in culture when isolated in vitro-HIV-infected CD4 cells were cocultured with Vδ2 cells.
We also show that blocking CD16, NKG2D and CD8 receptors, Vδ2 cell cytotoxic capacity is
partially inhibited suggesting that other receptors are also involved in exerting this function.
HIV can infect isolated γδ T cells in vitro [17,18]. In this study, we have shown that this
occurs through a mechanism that involves the transient upregulation of the CD4 receptor after
activation. CD4 expression is upregulated in Vδ2 cells in vitro following activation with IPP
and IL-2. This transient upregulation of CD4 has also been reported after infection of γδ T cells
with human herpesvirus [31]. Treatment with HMBPP and IL-2 also induced the expression of
CD4. Although the vast majority of Vδ2 lymphocytes do not express CD4, in the setting of
lymphopenia, rapid T-cell turnover, or heightened immune activation, increased IL-2 levels
could lead to CD4 upregulation in Vδ2 cells, making them susceptible to HIV infection in vivo.
We directly observed this phenomenon prior to ART in viremic, newly infected patients, sug-
gesting that this mechanism is plausible in vivo. Therefore, in addition to a previously reported
indirect mechanism to explain peripheral Vδ2 cell depletion [16], we describe a potential direct
effect of HIV infection on Vδ2 cell depletion. Direct infection of Vδ2 cells by HIV could lead to
depletion of most Vδ2, while others might survive and establish latent infection. Infection of
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Vδ2 cells can have significant consequences, as these cells constitute an important bridge
between the innate and adaptive immune response [32]. Therefore, due to reduced Vδ2 cell sig-
naling, dendritic cell function [33–36], follicular B cell help, or CD4+ T cell responses [37]
might be impaired.
In summary, our results demonstrate that Vδ2 cells are a novel latent reservoir for replica-
tion-competent HIV. Although these T lymphocytes are generally rare, the frequency of latent
infection in these cells makes it likely that they contribute measurably to the total burden of
latent, quiescent HIV infection. Moreover, we demonstrate that isolated Vδ2 cells can be
infected in vitro, and illustrate a mechanism that could allow γδ T cell infection despite consti-
tutive low expression of the CD4 receptor. We found that activation of Vδ2 cells upregulates
CD4 expression, enabling HIV infection. The durability of latent infection within this novel
cell population must still be established in longitudinal studies. However, given the broad
efforts to discover reagents that disrupt latency in resting CD4 central memory cells as a first
step towards viral eradication therapies, it may be necessary to also address the responsiveness
of proviral HIV genomes within resting γδ T cells to such strategies.
Materials and Methods
Patients and healthy donor volunteers
All patients provided written informed consent, and studies were approved by the UNC Insti-
tutional Review Board. Our criteria to define and select patients treated in acute HIV infection
(AHI) have previously been reported [38,39]. Briefly, patients identified in AHI (plasma HIV
RNA positive and HIVWestern blot negative) were enrolled and initiated ART within 45 days
of the estimated date of infection. Serial measurements of plasma viremia and CD4+ T cell
count were performed, and when patients were aviremic (<50 HIV RNA copies/ml) on ART
for>6 months, cells were obtained by continuous-flow leukapheresis. Patients studied after
initiation of ART in chronic HIV infection (CHI) had a history of stable, successful treatment,
and plasma HIV-1 RNA levels<50 copies/mL for>2 years without blips. Buffy coats from
uninfected donor volunteers were obtained from the New York Blood Center (Long Island
City, NY, USA).
High purity peripheral resting γδ T cell isolation
As part of the routine preparation for the outgrowth assay, prior to γδ T cell isolation, freshly
isolated patients’ PBMC were incubated with raltegravir and abacavir for 24 hours to avoid any
potential de novo infection due to HIV reactivation. For infectivity assays, isolated γδ T cells
from fresh PBMC from healthy non-HIV infected were used. γδ T cells were first enriched by
negative selection using a commercially available cocktail containing monoclonal antibodies
(mAb) directed against non-γδ cells, including antibodies against granulocytes, red blood cells,
dendritic cells, pan-αβ T cells, NK cells, stem cells, monocytes (StemCell Technologies, Van-
couver, Canada) and afterwards the cells were isolated by fluorescent activated cell sorting
(FACS) using a Reflection sorter (iCyt, Champagne, IL, USA) or a FACSAria II (BD). Each
sorting experiment was validated performing instrument quality controls, and running isotype
controls and fluorescence minus one control. In addition, gating strategy for each specific
experiment was based on the selection of the target cell by CD3 (clone SK7, BD) and Vδ2
(clone B6, Biolegend, San Diego, CA) mAbs, and exclusion of potential contamination of
CD4+ T cells in a third channel using the CD4 mAb (clone RPA-T4, BD), and in some experi-
ments αβTCR mAb (clone MOPC-21, Biolegend). To identify singlets we performed a 2-step
doublet discrimination using HxW of the pulse; first in the SSC direction then in the FSC direc-
tion. In all our preparations the singlets were always well separated from the doublets and no
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contamination with αβ T cells or CD4+ T cells was detected in the presort sample (Fig 1). In
addition, HLA-DR mAb (clone TU36, BD) was used to exclude potential pre-activated γδ T
cells, and fixable aqua (Life Technologies, Grand Island, NY) was used to exclude dead cells.
Cells were collected in RPMI-1640 containing stable Glutamine and Hepes (Gibco, Life Tech-
nologies, Grand Island, NY), 10% pooled human AB serum (Sigma-Aldrich, St Louis, MO)
and 10% PenStrep (Sigma-Aldrich) (hereafter referred to as γδmedium). After isolation, an ali-
quot was used to analyze the purity of the sorted population (> 99% γδ T cells,< 1% all other
cells) (Fig 1).
HIV outgrowth assays
After sorting, Vδ2 T cells were centrifuged and resuspended in the suitable volume of γδ
medium to perform the standardized co-culture assay [20,21]. As part of the standard method,
cells were plated in limiting dilution, when possible, and activated with 100nMHMBPP (kindly
provided by Dr. H. Jomaa, Justus-Liebig University, Giessen, Germany) or 1μM IPP (Sigma)
and 100U/mL IL-2 (Peprotech, Rocky Hill, CT) for 24 hours. In addition, as γδ T cell activation
requires the presence of APC [40] but γδ T cells and CD8+ T cells possess anti-HIV activity
[26], allogeneic non-HIV infected PBMC used as APC were first depleted of γδ T cells and
CD8+ T cells, added to cultures at a 1:4 ratio (isolated γδ T cells: PBMC depleted), and incu-
bated for 24 hours at 37°C and 5% CO2. Vδ2 cells were then washed and resuspended in γδ
medium containing 10U/mL IL-2 and cocultured with allogeneic PHA-activated PBMC
depleted of CD8+ T cells as target cells. CD8+ T cells were depleted by negative magnetic isola-
tion following manufacturer’s instructions (StemCell Technologies). Complete medium con-
taining 10U/mL IL-2 was replaced and refreshed every three or four days. Supernatants were
stored at -80°C for analysis of viral p24 production by ELISA (ABLinc, Rockville, MA, USA) at
days 15, and 19. As a control Vδ2 cells were cultured without activation prior to the addition of
target cells in 5U/mL IL-2, following the same coculture protocol, which were uniformly nega-
tive. Quantitative viral outgrowth assay for r-CD4 cells was performed in parallel using the
standard procedure previously reported in our lab [21,23,24] and described above also for γδ
cells. However, activation procedures were different between both cell populations. Briefly,
magnetically isolated r-CD4 cells were activated with 2μg/mL PHA, 60U/mL IL-2 and irradi-
ated PBMC from a non-infected donor, and target cells were added as previously reported and
as explained above. Infectious units per million Vδ2 and r-CD4 cells (IUPM) were calculated
using the R software developed at the University of North Carolina that allows calculating the
point estimate of the frequency of infection and the 95% confidence interval.
HIV DNA quantification
Total HIV pol DNA copies within isolated Vδ2 cells, unfractionated PBMC and resting CD4+
T cells were quantified by droplet digital PCR (ddPCR) using primers, probes and conditions
previously reported [41]. Briefly, DNA was extracted from frozen cell pellets of 1x105 Vδ2 cells
and 1x106 PBMC and r-CD4 cells on average, using the Qiagen DNeasy Blood and Tissue kit
(Qiagen, Maryland, USA) and concentration of DNA was measured using the Nanodrop
(Thermo Scientific). PCR reactions were loaded into the Bio-Rad QX-100 droplet generator.
Each reaction consisted of a 20μL mix containing 10 μL ddPCR Probe Supermix, 900 nM prim-
ers, 250 nM probe, and template DNA. Following amplification in a standard thermo cycler
(10 min. at 95°C, 40 cycles of 30 sec. at 94°C, 60 sec. at 58°C and final 10 min. at 98°C) droplets
were immediately analyzed as positive or negative using the Bio-Rad QX-100 droplet reader.
The no template controls were used to set the threshold, and copy number was calculated
using the manufacturer’s software and normalized to the total number of cells (Bio-Rad
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QuantaSoft v.1.2). As a control, dilutions of DNA from J89 cells, which contain a single copy of
HIV, was used in all runs. In addition, to control for the different number of cells assayed, we
run independent assays to compare HIV DNA levels in PBMC samples of 1x105 cells and
1x106 cells, which showed similar copy number.Samples were run in triplicate and the limit of
quantitation (LOQ) was calculated based upon the frequency of false positives in the no tem-
plate control.
Calculations of the contribution of HIV DNA to the HIV reservoir
We calculated the contribution of HIV DNA in Vδ2 cells and r-CD4 cells to the total
HIV-DNA+ PBMC as follows: First, we calculated the total HIV DNA copies in each cell popu-
lation by multiplying the average HIV copy number per million cells to the percentage of Vδ2
or r-CD4 cells present in total PBMC. Then, this total HIV copy number was divided by the
total HIV copy number in PBMC to obtain the proportion of HIV corresponding to Vδ2or r-
CD4 populations. Vδ2 cells contributed 1.6% and 8.1% to the total HIV DNA copy numbers in
PBMC of CHI and AHI patients, respectively. Resting CD4 T cells contributed 4.9% to the
total HIV DNA copy number in PBMC of CHI patients and 1.9% in AHI patients. None of the
comparisons between cell types or type of patients were statistically different.
Vδ2 cell HIV-infection assays
Freshly isolated Vδ2 cells from HIV-negative volunteers were activated using 100nM HMBPP
and 100U/mL IL-2 for 24 hours and spinoculated for 2 hours with 1ng/mL of the CCR5
JR-CSF strain. Cells were then washed twice to remove the excess of virus, cultured in triplicate
in γδmedium containing 20U/mL of IL-2 for 7 days and supernatants were analyzed for HIV
p24 production on days 4 and 7. As a control for the infection conditions, isolated CD4+ T cells
from the same uninfected blood donor volunteer were stimulated in parallel using 2μg/mL
PHA and 60U/mL IL-2. Supernatants from day 0 (basal levels after virus exposure) were also
stored and measured as a negative control. In some wells, Vδ2 cells and CD4 cells were incu-
bated with 50μg/mL of an anti-CD4 mAb (clone RPA-T4, BD) before exposure to HIV. Experi-
ment was repeated using three different donors.
HIV inhibition assays
Vδ2 and CD4+ T cells were FACS-sorted from PBMC of healthy donor volunteers. CD4 cells
were activated with 2μg/mL PHA and 60U/mL IL-2 for 24h washed and infected by spinocula-
tion with the viral strain JR-CSF following the same protocol described above, and co-cultured
in triplicate at different ratios of autologous Vδ2 cells (1:0.1 and 1:0.01 CD4:Vδ2). In some
wells cytotoxic activity of γδ cells was blocked using a mixture of purified mAb against CD8
and CD16 from Biolegend, and NKG2D fromMiltenyi Biotec. Media was refreshed at days 4
and 7 and supernatants stored until p24 ELISA quantification (ABLinc, Rockville, MA, USA).
Experiments were performed in three different donors.
Surface marker expression on Vδ2 cells
PBMC from healthy donor volunteers isolated from fresh buffy coats were incubated with 1μM
IPP and 100U/mL IL-2 or 100U/mL IL-2 alone. Expression of CD4 and CCR5 receptors along
with expression of activation markers HLA-DR, CD25 and CD38, was controlled by flow
cytometry at days 0 and six of culture. mAb used were; CD4-FITC (clone RPTA-4, BD),
Vδ2-PE (clone B6, Biolegend), CCR5-V450 (clone 2D7/CCR5, BD), HLA-DR-FITC (clone
TU36, BD), CD25-V450 (clone M-A251, BD) and CD38-PerCPCy5.5 (clone HIT2, BD).
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Briefly, cells were blocked with FBS (Sigma) for 10 minutes on ice, resuspended in staining
buffer (PBS-2% FBS), incubated for 20 minutes on ice in the dark with combinations of the
mAb, or suitable isotype controls, and washed twice. Cells were then fixed with 2% paraformal-
dehyde solution and analyzed in the Attune acoustic cytometer (Applied Biosystems).
Statistical analyses
Differences between patients treated in AHI and patients treated in CHI were compared using
the two-tailed Mann-Whitney U-test and comparisons between mean values were performed
by the two-tailed Student t-test. Statistical Analyses were performed using the IBM-SPSS ver-
sion 21.0 (Chicago, Illinois, USA) and p values<0.05 were considered statistically significant.
Supporting Information
S1 Fig. Recovery of replication-competent virus from the follow-up of two CHI-treated
patients.HIV was recovered in patients C.2 and C.3 when measured a second time after an
additional year of suppressive ART (sustained plasma viral load<50 copies/mL). Each square
represents one culture replicate that is represented in gray when replication-competent HIV
was recovered, and open squares represent culture replicates negative for HIV p24.
(TIF)
S2 Fig. Infection of isolated Vδ2 cells. Purified Vδ2 cells or CD4+ T cells from the same HIV-
uninfected donor were exposed to HIV JR-CSF. Vδ2 cells were activated prior to exposure to
HIV with HMBPP and IL-2. As a comparator, isolated CD4+ T cells were also infected follow-
ing PHA and IL-2 activation. Cells were successfully infected as demonstrated by production
of HIV p24 antigen after seven days of culture. Preincubation with anti-CD4 mAb prior to
exposure to HIV inhibited viral production, showing that infection was CD4-dependent.
(TIF)
S3 Fig. CD4 and CCR5 expression on Vδ2 cells. Flow cytometry analysis of CD4 and CCR5
expression on Vδ2 cells of a representative donor. Contour plots show the percentage of
peripheral Vδ2 cells comparing treatment with IL-2 alone IPP and IL-2 and IPP alone. Vδ2
cells expanded, while IL-2 alone did not induce an expansion of the cells. Contour plots in the
middle show CD4 and CCR5 expression on Vδ2 cells and lower plots show isotype controls.
(TIF)
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